<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>SAKK 38/19: ctDNA/PET-Guided Therapy in DLBCL</title>
    <meta name="study:id" content="sakk-38-19">
    <meta name="study:title" content="Oral 006 - SAKK 38/19: ctDNA and PET guided therapy in untreated DLBCL">
    <meta name="study:fileName" content="Abstracts/SAKK-38-19.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Acalabrutinib,BTK inhibitor,Rituximab,Monoclonal Antibody,Chemotherapy">
    <link rel="stylesheet" href="https-cdn.tailwindcss.com/_next/static/css/b72f5284a5279930.css">
    <link rel="stylesheet" href="abstract_styles.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <script src="https://cdn.jsdelivr.net/npm/d3@7"></script>
</head>

<body class="abstract-page-body">

    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: SAKK 38/19 - ctDNA/PET-Guided Therapy in 1L DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg style="color: var(--sobi-dark-blue)" xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24"><path d="M16 11c1.66 0 2.99-1.34 2.99-3S17.66 5 16 5c-1.66 0-3 1.34-3 3s1.34 3 3 3zm-8 0c1.66 0 2.99-1.34 2.99-3S9.66 5 8 5C6.34 5 5 6.34 5 8s1.34 3 3 3zm0 2c-2.33 0-7 1.17-7 3.5V19h14v-2.5c0-2.33-4.67-3.5-7-3.5zm8 0c-.29 0-.62.02-.97.05 1.16.84 1.97 1.97 1.97 3.45V19h6v-2.5c0-2.33-4.67-3.5-7-3.5z"/></svg>
                    <h4>Population & Aim</h4>
                    <p><strong>Population:</strong> N=124 untreated DLBCL (NOS) patients.</p>
                    <p><strong>Aim:</strong> To test the feasibility of a ctDNA and PET-guided adaptive therapy strategy.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg style="color: var(--sobi-teal)" xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24"><path d="M20.5 11H19V7c0-1.1-.9-2-2-2h-4c-1.1 0-2 .9-2 2v4h-1.5c-.83 0-1.5.67-1.5 1.5v4c0 .83.67 1.5 1.5 1.5H12v.5c0 .28.22.5.5.5h1c.28 0 .5-.22.5-.5V18h1.5c.83 0 1.5-.67 1.5-1.5v-4c0-.83-.67-1.5-1.5-1.5H16v-4h1v4.5c0 .28.22.5.5.5h1c.28 0 .5-.22.5-.5V12h1.5c.83 0 1.5-.67 1.5-1.5S21.33 11 20.5 11zM15 11h-2V8h2v3zM3.5 11H5v4H4v-4.5c0-.28-.22-.5-.5-.5h-1c-.28 0-.5.22-.5.5V12H1.5c-.83 0-1.5.67-1.5 1.5S.67 15 1.5 15H2v-.5c0-.28.22-.5.5-.5h1c.28 0 .5.22.5.5V15h1.5c.83 0 1.5-.67 1.5-1.5v-4C6.5 11.67 5.83 11 5 11h-1.5z"/></svg>
                    <h4>Intervention</h4>
                    <p><strong>Mutated (MYD88/CD79B):</strong> Acalabrutinib + R-CHOP.</p>
                    <p><strong>Wild-Type:</strong> R-CHOP, then therapy adapted based on interim PET/ctDNA status (escalation, de-escalation, or continuation).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg style="color: var(--sobi-orange)" xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24"><path d="M4 9h4v11H4zm0-5h4v4H4zm6 3h4v8h-4zm6 3h4v5h-4zm0-6h4v4h-4zm-6-4h4v4h-4z"/></svg>
                    <h4>Key Finding</h4>
                     <p>Interim Response (Post-C2):</p>
                    <span class="highlight-value">85%</span>
                    <p>of patients achieved ctDNA clearance, demonstrating rapid molecular response.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg style="color: var(--sobi-dark-blue)" xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-6h2v6zm0-8h-2V7h2v2z"/></svg>
                    <h4>Conclusion</h4>
                    <p>A ctDNA/PET-guided adaptive approach is feasible and operationally successful in a multicenter setting for 1L DLBCL.</p>
                </div>
            </div>
        </div>

        <h1 class="abstract-header-title">Oral 006: Feasibility of ctDNA and PET guided therapy in untreated DLBCL: Preliminary results of the SAKK 38/19 phase II trial</h1>
        <p class="abstract-sub-header">A. Stathis, A. Bruscaggin, F. Hitz, et al.</p>
        <p class="abstract-meta-info">Presented at the 18th International Conference on Malignant Lymphoma (ICML) | June 17-21, 2025</p>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Background</h2>
            <p>Diffuse large B-cell lymphoma (DLBCL) is an aggressive yet potentially curable disease. For decades, R-CHOP has remained the standard of care, with no alternative regimen demonstrating superior overall survival. The identification of molecular subtypes, such as those with MYD88 L265P and/or CD79A/B mutations, has opened avenues for targeted therapies like BTK inhibitors. This study explores the integration of circulating tumor DNA (ctDNA) analysis with PET imaging to refine risk stratification and guide therapy in real-time.</p>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Aims</h2>
            <p>The SAKK 38/19 trial is an exploratory, multicohort phase II study with dual objectives:</p>
            <ul class="list-disc pl-5 mt-2">
                <li>To evaluate the efficacy of adding acalabrutinib to R-CHOP (A-R-CHOP) in treatment-naïve DLBCL patients with MYD88 and/or CD79A/B mutations.</li>
                <li>To evaluate the feasibility and outcomes of a ctDNA and PET-adapted treatment strategy for patients without these mutations, involving:
                    <ul class="list-circle pl-5 mt-1">
                        <li><strong>Treatment Escalation:</strong> For patients remaining PET-positive and ctDNA-positive after two cycles of R-CHOP.</li>
                        <li><strong>Treatment De-escalation:</strong> For patients who become PET-negative and ctDNA-negative after two cycles of R-CHOP.</li>
                    </ul>
                </li>
            </ul>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Methods & Study Design</h2>
            <p>This investigator-initiated trial enrolled treatment-naïve patients with Stage I-IV DLBCL (NOS) who were eligible for R-CHOP and had quantifiable ctDNA. Patients were centrally screened for MYD88 L265P and/or CD79A/B mutations via a CAPP-seq assay to determine cohort allocation.</p>
            <h3 class="abstract-sub-section-title">Study Schema</h3>
            <div class="study-design-schema">
                <div class="schema-title">SAKK 38/19 Treatment Allocation</div>
                <div class="flex items-center justify-center">
                    <div class="schema-enrollment">
                        <strong>Enrollment</strong>
                        <span>Untreated DLBCL</span>
                        <span>ctDNA analysis for MYD88/CD79A/B mutations</span>
                    </div>
                </div>
                <div class="flex mt-4">
                    <div class="w-1/2 pr-4 border-r-2 border-dashed border-gray-400">
                        <div class="text-center font-bold text-teal-600 mb-2">Mut. + (Cohort A)</div>
                        <div class="flex items-center">
                             <div class="schema-phase flex-1"><strong>6 Cycles</strong><div>Acalabrutinib + R-CHOP</div></div>
                             <div class="schema-arrow">&rarr;</div>
                             <div class="schema-phase"><strong>EoT Assessment</strong><div>PET/ctDNA</div></div>
                        </div>
                    </div>
                    <div class="w-1/2 pl-4">
                        <div class="text-center font-bold text-blue-800 mb-2">Mut. - (Cohorts B, C, D)</div>
                        <div class="flex items-center mb-2">
                            <div class="schema-phase flex-1"><strong>2 Cycles</strong><div>R-CHOP</div></div>
                            <div class="schema-arrow">&rarr;</div>
                            <div class="schema-phase"><strong>Interim Assessment</strong><div>PET/ctDNA after C2</div></div>
                        </div>
                        <div class="schema-arrow-down">&#8595;</div>
                        <div class="space-y-2 mt-2">
                            <div class="border p-2 rounded-md bg-red-50 border-red-200">
                                <strong>Cohort B (Escalation): PET+ / ctDNA+</strong>
                                <div class="flex items-center text-sm"><div class="schema-phase flex-1">4 Cycles A-R-CHOP</div></div>
                            </div>
                            <div class="border p-2 rounded-md bg-green-50 border-green-200">
                                <strong>Cohort C (De-escalation): PET- / ctDNA-</strong>
                                <div class="flex items-center text-sm"><div class="schema-phase flex-1">2 Cycles R-CHOP + 2 Cycles Rituximab</div></div>
                            </div>
                            <div class="border p-2 rounded-md bg-yellow-50 border-yellow-200">
                                <strong>Cohort D (Continuation): Discordant PET/ctDNA</strong>
                                <div class="flex items-center text-sm"><div class="schema-phase flex-1">4 Cycles R-CHOP</div></div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
             <h3 class="abstract-sub-section-title">Endpoints</h3>
            <ul class="list-disc pl-5">
                <li><strong>Primary Endpoints:</strong> Progression-Free Survival (PFS) for cohorts A, C, and D; Complete Response Rate (CRR) for cohort B.</li>
                <li><strong>Secondary Endpoints:</strong> Included Overall Survival (OS), safety, ORR, and Duration of Response (DOR).</li>
            </ul>
        </div>
        
        <div class="abstract-card">
            <h2 class="abstract-section-title">Patient Characteristics & Feasibility</h2>
            <p>Out of 230 screened patients, 124 were included in the Full Analysis Set (FAS). The median time from informed consent to treatment start was 15 days, including a median ctDNA turnaround time of 9 days, demonstrating the operational feasibility of this approach.</p>
            <div class="table-container">
                <table>
                    <thead>
                        <tr>
                            <th>Characteristic</th>
                            <th>Value (N=124)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr><td>Median Age (range), years</td><td>65 (24-91)</td></tr>
                        <tr><td>Ann Arbor Stage III-IV</td><td>72.6%</td></tr>
                        <tr><td>IPI Score 3-5</td><td>45.9% (29.8% + 16.1%)</td></tr>
                        <tr><td>Bulky Disease (≥7.5 cm)</td><td>29.8%</td></tr>
                        <tr><td>Cell of Origin (COO) - non-GCB</td><td>54.8%</td></tr>
                        <tr><td>Extranodal Disease</td><td>64.5%</td></tr>
                    </tbody>
                </table>
            </div>
            <h3 class="abstract-sub-section-title">Cohort Allocation (FAS, N=124)</h3>
            <div class="table-container">
                <table>
                     <thead>
                        <tr><th>Cohort</th><th>Description</th><th>Patients, n (%)</th></tr>
                    </thead>
                    <tbody>
                        <tr><td>A</td><td>Mutated (MYD88/CD79B)</td><td>27 (21.8%)</td></tr>
                        <tr><td>B</td><td>WT, PET+/ctDNA+ (Escalation)</td><td>8 (6.5%)</td></tr>
                        <tr><td>C</td><td>WT, PET-/ctDNA- (De-escalation)</td><td>38 (30.6%)</td></tr>
                        <tr><td>D</td><td>WT, Discordant (Continuation)</td><td>44 (36.5%)</td></tr>
                    </tbody>
                </table>
            </div>
        </div>
        
        <div class="abstract-card">
            <h2 class="abstract-section-title">Preliminary Results</h2>
            <h3 class="abstract-sub-section-title">PET and ctDNA Response</h3>
            <p>Molecular response was rapid and deep for the majority of patients. Baseline ctDNA levels were found to significantly correlate with adverse prognostic factors like high IPI score, bulky disease, B symptoms, and high tumor burden as measured by MTV and TLG on PET scans.</p>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                <div>
                    <h4 class="font-semibold text-center mt-2">Response After 2 Cycles (N=124)</h4>
                    <div class="table-container">
                         <table>
                            <thead>
                                <tr><th>Status</th><th>PET Negative (DS 1-3)</th><th>PET Positive (DS 4-5)</th><th>Total</th></tr>
                            </thead>
                            <tbody>
                                <tr><td><strong>ctDNA Negative</strong></td><td>49 (87.5%)</td><td>56 (85.9%)</td><td><strong>105 (84.7%)</strong></td></tr>
                                <tr><td><strong>ctDNA Positive</strong></td><td>3 (5.4%)</td><td>9 (14.1%)</td><td><strong>12 (9.7%)</strong></td></tr>
                            </tbody>
                        </table>
                        <p class="footnote-text">*Adapted from slide 26. Percentages calculated within PET status columns.</p>
                    </div>
                </div>
                 <div>
                    <h4 class="font-semibold text-center mt-2">Response at End of Treatment (N=124)</h4>
                     <div class="table-container">
                        <table>
                           <thead>
                                <tr><th>Status</th><th>PET Negative (DS 1-3)</th><th>PET Positive (DS 4-5)</th><th>Total</th></tr>
                            </thead>
                            <tbody>
                                <tr><td><strong>ctDNA Negative</strong></td><td>70 (89.7%)</td><td>21 (84.0%)</td><td><strong>99 (79.8%)</strong></td></tr>
                                <tr><td><strong>ctDNA Positive</strong></td><td>2 (2.6%)</td><td>4 (16.0%)</td><td><strong>9 (7.3%)</strong></td></tr>
                            </tbody>
                        </table>
                         <p class="footnote-text">*Adapted from slide 27. Percentages calculated within PET status columns.</p>
                    </div>
                </div>
            </div>
             <h3 class="abstract-sub-section-title">Predictors of End of Treatment PET</h3>
             <p>High baseline Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) were significant predictors of having a positive PET scan at the end of treatment (p=0.013 and p=0.026, respectively). For patients who were PET positive after 2 cycles, achieving ctDNA negativity showed a non-significant trend towards having a negative PET at EoT.</p>
        </div>
        
        <div class="abstract-card">
             <h2 class="abstract-section-title">Safety</h2>
             <p>A detailed analysis of adverse events was a secondary endpoint of the study but was not presented in this preliminary report.</p>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <p>The SAKK 38/19 trial successfully demonstrates that a complex PET- and ctDNA-guided therapeutic strategy is feasible within a multicenter trial setting, with efficient sample processing and timely treatment allocation.</p>
            <ul class="list-disc pl-5 mt-2">
                <li>Baseline ctDNA levels correlate strongly with established prognostic markers like IPI, bulky disease, and PET-derived tumor burden (MTV/TLG).</li>
                <li>High baseline MTV and TLG were predictive of remaining PET-positive at the end of treatment.</li>
                <li>There was a trend toward correlation between ctDNA clearance at cycle 2 and achieving a negative PET scan at the end of treatment, though this was not statistically significant.</li>
                <li>The results from Cohort A will provide valuable insights into the role of BTK inhibition in a genetically defined DLBCL population, while the outcomes of the response-adapted cohorts (B, C, and D) will inform the design of future randomized trials.</li>
            </ul>
        </div>
        
        <div class="abstract-card">
             <h2 class="abstract-section-title" id="referenceSection">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference to Clipboard">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M7 3.5A1.5 1.5 0 018.5 2h5A1.5 1.5 0 0115 3.5v10A1.5 1.5 0 0113.5 15h-5A1.5 1.5 0 017 13.5v-10zM8.5 3a.5.5 0 00-.5.5v10a.5.5 0 00.5.5h5a.5.5 0 00.5-.5v-10a.5.5 0 00-.5-.5h-5z"></path><path d="M4.5 5A1.5 1.5 0 003 6.5v10A1.5 1.5 0 004.5 18h5A1.5 1.5 0 0011 16.5V16h-1v.5a.5.5 0 01-.5.5h-5a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5H5V5h-.5z"></path></svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Stathis A, Bruscaggin A, Hitz F, et al. Feasibility of ctDNA and PET guided therapy in untreated DLBCL: preliminary results of the SAKK 38/19 phase II trial. Abstract #Oral 006 presented at the 18th International Conference on Malignant Lymphoma (ICML). 17-21 June 2025, Lugano, Switzerland.</p>
        </div>

        <div class="abstract-footer-info">
            <p><strong>Trial Identifier:</strong> NCT04604067</p>
            <p>Abstract ID: sakk-38-19</p>
        </div>
    </div>
    <script src="../abstract_features.js"></script>
</body>
</html>